Biohaven Ltd. (BHVN) announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) seeking approval of VYGLXIA (troriluzole) for the treatment of spinocerebellar ataxia (SCA).
The company noted that the CRL was issued despite Study 206-RWE being reviewed by the FDA and achieving statistical significance in its prespecified primary and secondary efficacy endpoints. The FDA cited concerns commonly associated with real-world evidence and external control studies, including potential bias, design flaws, lack of pre-specification, and unmeasured confounding factors.
Biohaven said it remains committed to working with the FDA to find a path forward for its NDA for VYGLXIA and plans to meet with the FDA to discuss potential next steps.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.